MetaCap

aTyr Pharma (ATYR) vs IN8bio (INAB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

aTyr Pharma (ATYR) has outperformed IN8bio (INAB) over the past year, gaining 474.4% versus a loss of 55.4%. Over five years, ATYR leads with a -52.6% price change compared with -99.6% for INAB. aTyr Pharma is the larger company by market cap ($9.7 million vs $8.2 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ATYR+474.44%INAB-55.41%
+1096%+479%-137%
Nov 21, 20251 yearNov 20, 2026
ATYR-53.41%INAB-99.63%
+5%-50%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ATYR versus INAB key metrics
MetricATYRINAB
Share price$3.82$0.758
Market cap$9.74M$8.19M
1-day change+3.52%-1.86%
YTD return+387.87%-67.61%
1-year return+474.44%-55.41%
5-year return-52.61%-99.63%
EPS (TTM)$-21.64$-1.00
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$190.00K—
Revenue growth (YoY)-19.15%—
Net income (latest FY)$-74.12M$-19.44M
Operating margin-40856.32%—
Net margin-39009.47%—
52-week high$44.40$2.73
52-week low$3.69$0.724
Distance from 52-week high-91.40%-72.23%
Analyst consensusbuynone
Avg. price target upside-25.13%+823.48%
Average volume115.38K120.61K
Shares outstanding2.55M10.81M
Employees5818
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ATYR has outperformed INAB by 529.8 percentage points over the past year.

About aTyr Pharma

ATYR stock →

aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 58 employees

About IN8bio

INAB stock →

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees

ATYR vs INAB FAQ

Which is bigger, aTyr Pharma or IN8bio?

aTyr Pharma (ATYR) is larger, with a market capitalization of $9.74M compared with $8.19M for IN8bio (INAB).

Which stock has performed better over the past year, ATYR or INAB?

ATYR returned +474.44% over the past 12 months, compared with -55.41% for INAB (price return, excluding dividends). Past performance does not predict future results.

Are aTyr Pharma and IN8bio in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons